Search
Ontuxizumab
go.drugbank.com/drugs/DB16270InvestigationalOntuxizumab is a humanized monoclonal antibody that targets endosialin or tumour endothelial marker 1 (TEM-1).
Mevidalen
go.drugbank.com/drugs/DB19034InvestigationalMevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or
Ulixertinib
go.drugbank.com/drugs/DB13930InvestigationalIt is currently in clinical trials for the treatment of a wide range of tumors.
Thiostrepton
go.drugbank.com/drugs/DB11467InvestigationalVet approvedThiostrepton is a natural product of the ribosomally synthesized and post-translationally modified peptide class.
S-3304
go.drugbank.com/drugs/DB12149InvestigationalS-3304 has been used in trials studying the treatment of Lung Cancer, Solid Tumors, Non Small Cell Lung Cancer, Stage IIIB Non Small Cell Lung Cancer, and Stage IIIA Non Small Cell Lung Cancer, among others
Reparixin
go.drugbank.com/drugs/DB12614InvestigationalReparixin has been used in trials studying the treatment and prevention of Breast Cancer, Metastatic Breast Cancer, Pancreatectomy for Chronic Pancreatitis, Islet Transplantation in Diabetes Mellitus Type
Onapristone
go.drugbank.com/drugs/DB12637InvestigationalOnapristone has been used in trials studying the treatment of Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Androgen-independent Prostate Cancer, and Progesterone Receptor Positive
Puromycin
go.drugbank.com/drugs/DB08437ExperimentalPuromycin is toxic to both prokaryotic and eukaryotic cells, resulting in significant cell death at appropriate doses.
Palucorcel
go.drugbank.com/drugs/DB17955InvestigationalDeveloped by Janssen Biotech, it is being investigated for the treatment of various conditions such as amyotrophic lateral sclerosis (ALS) and macular degeneration.
Ripertamab
go.drugbank.com/drugs/DB16314InvestigationalRipertamab is under investigation in clinical trial NCT02772822 (A Study Comparing the Efficiency and Safety of S-chop(cyclophosphamide, Hydroxydaunomycin, Oncovin, and Prednisone) Versus R-CHOP in Untreated